COMPASS PATHWAYS Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026 Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026 Cash position of $185.9 million as of September 30, 2025 Conference call on November 4 at 8 am ET (1 pm UK) LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch ...

LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a particular focus on neuroscience. As part of this Board transition, Thomas Lönngren will retire from his position on the Board at the end of December after more than six years of service. Mr. Lönngren has been an invaluable counselor across the company's achievements, including the advancement of the COMP360 program and transition from an early-stage to late-stage clinical company. “With Compass leading the field of psychedelics and looking ahead to potential commercialization for COMP360, we are grateful to have Dr. Jonas' extensive experience in neuroscience, an area in which he has consistently...

Compass management will host a conference call at 8:00 am ET (1:00 pm UK)LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/698442687. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by exi...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Positive primary endpoint achieved in first COMP360 Phase 3 trial with high statistical significance, clinically meaningful reduction in depression at 6 weeks, and no unexpected safety findings Second ongoing pivotal Phase 3 trial continues to enroll well, with 26-week data expected in the second half of 2026 Compass exploring options for potential accelerated COMP360 filing for TRD Cash position of $221.9 million at June 30, 2025; cash runway into 2027 Conference call on July 31 at 8:00 am ET (1:00 pm UK) LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2025 and provided an update on recent progress across its business. “With the recent positive 6-week primary endpoint from our first COMP360 Phase 3 study and the prior positive Phase 2b study, we have now delivered clinically meaningful and hig...

On today's episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca discusses the company's quarterly earnings. Kabir Nath, Chief Executive Officer of Compass Pathways, on the pursuit of FDA approval of the first psychedelic treatment for certain people living with depression. Also, Bloomberg's Molly Smith and Oliver Crook on US-China Trade talks and the FOMC meeting (Source: Bloomberg)...

RFK Jr. earlier this month said he could envision approval for psychedelic drugs as treatment for depression and trauma if clinical studies have been conducted. Kabir Nath, CEO of Compass Pathways, makers of synthetic psilocybin told Bloomberg Businessweek Daily, his company has completed promising clinical studies for the treatment of depression. (Source: Bloomberg)...

LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Justin Gover to its Board of Directors, effective immediately. Mr. Gover brings more than 25 years of leadership in the biopharmaceutical industry to this role. As part of this Board transition, Dr. Linda McGoldrick will retire from her position on the Board at the end of October after more than 5 years of service. Having helped guide Compass's growth through its 2020 initial public offering and early clinical milestones, Dr. McGoldrick has been a key and invaluable counselor in the company's achievements. “With the achievement of the primary endpoint in our first Phase 3 trial, we're entering an exciting next stage on our journey towards potential approval and commercialization. Justin brings a deep understanding of our industry and a commitment to executional excelle...

Compass management will host a conference call at 8:00 am ET (1:00 pm UK)LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments...

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics....

read more...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Compass Pathways Plc. said its psychedelic drug to treat a form of depression met its goal in a late-stage trial, but it may not be enough for investors....

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second half of 2026 Cash position of $260.1 million at March 31, 2025 Conference call on May 8 at 8:00 am ET (1:00 pm UK) LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. “We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said Kabir Nath, Chief Executive Officer. “Our continued progress reinforces Compass' leadership in psychedelic therapy development, which we believe represents the next generation of mental health therapeutic o...